PT-141 & Bremelanotide: FDA, Vyleesi & Safety Status

FDA approval date

FDA approved the drug product Vyleesi, containing bremelanotide, on June 21, 2019. The file is NDA 210557. This page does not write that “PT-141 is FDA approved for all uses.”¹

Exact indication

The current indication is treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD), where low sexual desire causes marked distress or interpersonal difficulty and is not due to a co-existing medical or psychiatric condition, relationship problems, or the effects of a medication or other drug.²

What is not indicated

• It is not indicated for postmenopausal women.
• It is not indicated for men.
• It is not indicated to enhance sexual performance.
• It does not turn a Peptra RUO material into the approved product.

Those limits appear on the label. They must stay visible. They are not diluted into a broad sentence about “sexual dysfunction.”²

Current marketed formulation

The marketed product is a bremelanotide acetate formulation. The active moiety is bremelanotide. A research vial that does not document acetate is not described as that formulation.²

Major labeled safety topics

This section summarizes label topics. It is not a treatment guide and it does not reproduce administration instructions.

Mechanism uncertainty

The label describes bremelanotide as a melanocortin receptor agonist. At approved-product exposure, it identifies MC1R and MC4R as particularly relevant. It also states that the exact mechanism by which Vyleesi improves HSDD is unknown.²

Phase 3 outcomes in their context

The Phase 3 trials showed a statistically significant difference in desire and in distress. They did not show a significant difference in the number of satisfying sexual events. Those three facts belong to the approved population. They are not turned into “raises libido in everyone.”^2,3

RUO / pharmaceutical-product separation

A “research use only” label does not protect the surrounding context. If content around a peptide demonstrates intended human use, the frame is no longer documentary. That is why this page and the commercial listing stay separate: evidence and limits live here; an analytical material lives there.⁴

Those three safety topics are summarized because they appear on the approved-product label. They are not turned into a list of “what to expect if a research vial is used.” The Peptra vial is not that product. A reaction described for Vyleesi is not transferred to a lyophilizate because a development name is shared. This page also offers no management tip, no threshold, and no administration sequence.²

Hyperpigmentation, in particular, stays on the MC1R shelf. The label connects that receptor with melanin. That explains a risk described for the approved product. It does not authorize a cosmetic use or a pigment promise. A receptor that participates in pigmentation is not translated into a beauty claim.²

The August 2026 warning letter is used only as an editorial lesson. It recalled that a peptide sold as a research chemical can be read as a new drug if surrounding content demonstrates intended human use. That is why this page does not name a seller and does not become an attack. The point is internal: the commercial listing and the research stay in different voices.⁴

United States versus Mexico

The approval described here is a U.S. FDA approval. COFEPRIS status is not inferred from that approval. A file in one country does not demonstrate authorization in the other.

That border matters on a site that speaks to readers in Spanish and in English. A 2019 date on a U.S. NDA does not translate into a Mexican authorization. A vacuum is not invented either. The limit is stated: this review covers the FDA label and approval letter, read as of September 1, 2026. What is not in that file is not filled by analogy.^1,2

A WADA status is not assigned either. In the official list reviewed, the exact name bremelanotide or PT-141 was not identified in a way that supports saying permitted, prohibited, or TUE-required. Without that anchor, this page does not open an anti-doping section. An honest silence is better than an invented classification.

This page’s evidence-reviewed date is September 1, 2026. That stamp does not mean approval changed on that day. It means the label, the approval letter, and the limits were read against the file available on that date. If a later editor updates the text, that date should be updated too, rather than leaving an old indication dressed as current status.

The unknown mechanism is repeated at the close because it is the antidote to a lazy headline. It is fair to say bremelanotide is a melanocortin agonist. It is not fair, on this label, to say the exact mechanism by which Vyleesi improves HSDD is known. Both sentences can coexist. The second is not sacrificed so that the first sounds more settled.²

Next reading

• Separate moiety, acetate, Vyleesi, and the RUO vial
• See desire, distress, and satisfying events
• Back to the research hub